Precision brain stimulation to reduce cannabis craving in people with schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study uses personalized repetitive transcranial magnetic stimulation (rTMS) protocols to target different brain networks: the default mode network (DMN) in participants with schizophrenia and the left dorsolateral prefrontal cortex (L DLPFC) in healthy cannabis users. Participants receive brief intermittent and continuous theta-burst stimulation sessions while researchers measure changes in brain network activity, cue-induced craving, and cognitive performance. The trial enrolls adults 18–65 who are outpatient-stable, currently use cannabis (urine-confirmed), and can complete study procedures. Vanderbilt University Medical Center conducts the imaging, stimulation, and behavioral testing at its psychiatric hospital in Nashville, TN.

Why it matters

Who can join: the full rules

Inclusion Criteria for Psychosis Participants:

* Age between 18-65 years
* Diagnosis of a psychotic disorder according to DSM-5 criteria and confirmed by SCID
* Current cannabis use of at least 2/10 on a Visual Analog Scale
* Current cannabis use (confirmed by urine cannabis testing)
* Must be able to read, speak and understand English
* Must be judged by study staff to be capable of completing the study procedures
* Participants will be in stable outpatient psychiatric treatment and psychiatrically stable with no recent (within the past 30 days) psychiatric hospitalizations or changes in their psychiatric medication regimens.

Inclusion Criteria for Healthy Controls:

\- All of the above except for participants will not have a diagnosis of a psychotic disorder nor a first-degree relative with a psychotic disorder.

Exclusion Criteria for ALL participants:

* DSM-5 intellectual disability
* Substance use disorder (other than cannabis or nicotine) within the past three months
* Positive urine drug screen for illicit substance use that can increase seizure risk (cocaine, benzodiazepines, amphetamine, methamphetamine)
* Any history of a progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tuberous sclerosis, Alzheimer's Disease) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions
* History of head trauma resulting in any loss of consciousness (\>15 minutes) or neurological sequelae
* Current history of poorly controlled headaches including chronic medication for migraine prevention
* History of fainting spells of unknown or undetermined etiology that might constitute seizures
* History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
* Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
* Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)
* Any devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible covering MD
* All female participants of child-bearing age will be required to have a pregnancy test; any participant who is pregnant or planning to become pregnant will not be enrolled in the study
* Medications will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and use of CNS active drugs. The published TMS guidelines review of medications to be considered with rTMS will be taken into consideration given their described effects on cortical excitability measures.
* Any changes in medications or hospitalizations within the past 30 days.
* Participants who, in the investigator's opinion, might not be suitable for the study or would be unable to tolerate the study visit

These exclusion criteria strictly follow all recommended guidelines as endorsed by the International Federation of Clinical Neurophysiology and the International Society for Transcranial Stimulation.

Where it's running

• Vanderbilt Psychiatric Hospital
  Nashville, Tennessee, United States Recruiting

Study contacts

• Study coordinator: Jillian G Connolly, B.S.
• Email: jillian.connolly@vumc.org
• Phone: 6154345891

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Investigating cognitive function in psychosis patients and cannabis users

  This study is testing how taking a break from cannabis for 28 days affects thinking skills and brain activity in people with psychosis and those who use cannabis but don’t have mental health issues.

  Recruiting Douglas Mental Health University Institute · Montreal, Quebec · NCT05445180

• Genetic counselling to prevent mental health issues from cannabis use

  This study is trying to see if genetic counselling can help young people aged 12 to 21 understand their risk of mental health issues from cannabis use and make better choices about using it.

  Recruiting Nova Scotia Health Authority · Halifax, Nova Scotia · NCT03601026

• State Representation in Early Psychosis 2

  This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.

  Recruiting at 2 sites University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT07834203

• Trying the Kiso Mind smartphone app for people with schizophrenia spectrum disorders

  This study tests whether the Kiso Mind smartphone app is acceptable, practical, and helpful for adults with schizophrenia or schizoaffective disorder alongside their usual care.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07395206

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.